Navigation Links
1 step closer to a drug treatment for cystic fibrosis, MU professor says
Date:10/12/2010

COLUMBIA, Mo. A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

The Journal of Biological Chemistry has published findings by Tzyh-Chang Hwang, a professor in the School of Medicine's Department of Medical Pharmacology and Physiology and the Dalton Cardiovascular Research Center. The publication has been recognized as the "paper of the week" for the journal, meaning Hwang's work is considered to be in the top 1 percent of papers reviewed annually in terms of significance and overall importance.

Hwang's work focuses on the two most common genetic mutations among approximately 1,500 mutations found in patients with cystic fibrosis. These two mutations cause specific chloride channels in the cell, known as the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride channels, to malfunction. This ultimately leads to repeated pneumonia, the primary cause of most deaths associated with cystic fibrosis.

"The normal function of a cell is to pass chloride ions across the cell membrane at a very fast speed," Hwang said. "We know some signaling molecules elicit this reaction, much like a hand signals an automatic water faucet to dispense water. But in the case of cystic fibrosis, that signal is no longer detected by the mutated channel protein. Through some mechanisms we still don't quite understand, malfunction of this channel protein eventually leads to bacterial infection in the lung, which is believed to be responsible for the most severe symptoms of cystic fibrosis."

The most recent study found that manipulating the sensor of the channel protein can significantly rectify the malfunction of the mutated channel, thus opening the door to a drug design that may eventually be a "real cure," Hwang said.

"We could help a lot of patients if we can utilize the power of computer simulations and
'/>"/>

Contact: Steven Adams
AdamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Plant scientists move closer to making any crop drought-tolerant
2. Solid oxide fuel cells getting closer to the market
3. Gene therapy a step closer to mass production
4. Research is getting closer to understanding critical nucleus in haze formation, prof says
5. Genome BC, Chile and Norway take another step closer to fully sequencing the salmon genome
6. Low-cost, ultra-fast DNA sequencing brings diagnostic use closer
7. For osteoporosis patients, exercise pill one step closer to reality
8. Bringing better grapes a step closer to reality
9. Cold fusion moves closer to mainstream acceptance
10. 1 step closer to closure
11. ESA and World Bank move toward closer collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Grand Canyon may be so old that dinosaurs once lumbered ... the University of Colorado at Boulder and the California Institute ... radiometric dating to show the Grand Canyon may have formed ... origins by 40 million to 50 million years. The ...
... researchers is needed to make progress towards one ... marks contribute to regulation of gene expression. This ... European Science Foundation (ESF), Computational Approaches to the ... Epigenetics studies features of the DNA and chromatin ...
... NEW YORK, April 9 e-Smart(R) Technologies,Inc. ... and its parent,company, IVI Smart Technologies, Inc., ... filed in a Motion last month by,IDsmart ... Northern District of,California, San Francisco Division, Case ...
Cached Biology News:Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Computation to unravel how genes are regulated and shed light on how cells become different 2Computation to unravel how genes are regulated and shed light on how cells become different 3IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 2IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 3
(Date:10/25/2014)... Oct 24, 2014 Research and Markets ... Market by Product , Research Area & by End ... their offering. In this report, the ... products, research areas, and end users. The product segments ... enzymes, instruments & consumables, kits, and reagents. The subsegments ...
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... next steps for its Oral Amphotericin B program.  ... in vitro work involving samples from ... plans to complete pre clinical studies and regulatory ... 1A clinical trial, utilizing approximately $700,000 of funding ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... July 10 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... European Medicines Agency (EMEA) for ranolazine for,the treatment of ... (EU),member states. This approval follows a positive opinion from ... on April 24, 2008., Ranolazine is approved for ...
... MADISON, N.J., July 10 Quest Diagnostics,Incorporated (NYSE: ... and services, announced today that its second-quarter,2008 results will ... market,opens, and that it will hold its quarterly conference ... a.m. ET on that day., The public may ...
... Inc. (Nasdaq: ALXN ), today announced that the ... on Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time ... for the second quarter ended June 30, 2008. Alexion,anticipates ... Tuesday,July 29, 2008., To participate in this conference ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
Ephrin A4...
Rad51B...
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
... reactive against the complex IV assembly factor SURF1. ... cultured cells. SURF1 is an important assembly factor ... participate in the folding of subunit II and ... SURF1, particularly ones that result in an absence ...
Biology Products: